In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research ...

Vertex Solutions, a small business known for the manufacturing of systems integration and advanced training technologies, has ...

Vertex, Inc. (NASDAQ: VERX) has announced plans to release its first quarter 2025 financial results on Wednesday, May 7, 2025 ...

KING OF PRUSSIA, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release first ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

CANON announced the EOS R50 V, PowerShot V1 and RF-S14-30mm f/4-6.3 IS STM PZ, three new products that supplement Canon’s existing product lineups with ...

The Medicines and Healthcare products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy ...